Released Nov 3, 2026, before the open
10-Q filed Nov 3, 2026, 34 days after period end · 0001816590-26-000076
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$9.83M | -$137.72M | -$38.50M | -$33.39M |
| EPS Diluted | -$0.31 | -$1.44 | -$0.56 | -$0.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
COMPASS Pathways plc · CIK 1816590 · Engraved from SEC EDGAR
Research and development expenses were $23.5 million and $79.1 million for the three and nine months ended September 30, 2026, compared with $27.3 million and $88.5 million in the same periods of 2025.¶1
Selling, general and administrative expenses were $33.0 million and $72.6 million for the three and nine months ended September 30, 2026, compared with $13.2 million and $44.6 million in 2025, reflecting commercial preparedness costs.¶2
Net loss was $9.8 million, or $0.07 per basic share, for the three months, and $172.4 million, or $1.35 per share, for the nine months ended September 30, 2026, with warrant fair value changes driving the decrease.¶3
Cash and cash equivalents were $444.0 million as of September 30, 2026, and the company said this position is expected to fund operations into 2028.¶4¶5